Jul 14, 2011
Eat broccoli and live longer
Jul 5, 2011
Could a Diet Help Prevent Alzheimer's?
Jul 1, 2011
FDA Approves HER2 Test for Breast Cancer
Jun 20, 2011
Scientists Identify Genes Linked to Migraines
Mar 1, 2010
Pharmacogenomics: Personalized Medicine at the Corner Drugstore
MayoClinic.com, GoogleNews.com, February 24, 2010, by Carrie A. Zabel – Personalized medicine offered at your local drugstore?
Two large prescription drug companies have announced plans to offer genetic testing as part of the prescription-filling process. The testing will center on an emerging science, pharmacogenomics, which studies drug response based upon an individual’s genetic make-up. Pharmacogenomic testing is already used for some commonly prescribed drugs such as Tamoxifen and Warfarin.
The process would use a pharmacy benefits management company that would contract with large drugstore chains. When certain prescriptions come in, the company would contact the physician to let them know a genetic test is available, which may help them to more appropriately prescribe that medication. The individual may then be offered the genetic testing, but it wouldn’t be required.
Supporters say this will improve patient safety, health outcomes and decrease overall health care costs by using the right medications in the right patients. It may also provide an opportunity to advance the field of pharmacogenomics by collecting data on genetic testing results and drug effectiveness.
Others are concerned about the privacy of genetic testing information and say the science of pharmacogenomics is premature. Drug metabolism isn’t only based on our genetic make-up, but is affected by many additional factors, such as body size and age. And, since pharmacogenomics is a relatively new science, insurance companies may not reimburse for the cost of genetic testing.
Carrie A. Zabel, M.S., C.G.C., Genetic Counselor
Feb 16, 2010
Identification of bipolar risk gene
A collaboration, led by scientists at the Garvan Institute of Medical Research and the University of New South Wales (UNSW) in Sydney, has discovered the first risk gene specifically for bipolar disorder, also known as manic-depressive illness. This means that people who have a particular form of this gene are twice as likely to develop the disease.
Lead author, Dr Ian Blair, says: “We are the first group in the world to take a multi-faceted approach to identify a bipolar risk gene - we used a number of families, unrelated patients, and therapeutic drug mouse models. Each of these three lines of investigation led us to a gene called FAT.”
Contributing author Professor Phil Mitchell, Head of Psychiatry at UNSW, says: “Over the last twenty years we have collected blood samples from 67 families right across Australia. This amounts to hundreds of family members (904), some of whom are spread across four generations. This was a strong starting point in our hunt for a Bipolar gene.”
"We know that the FAT gene codes for a protein that is involved in connecting brain cells together, what we need to do now is find out exactly how it contributes to the increased risk of bipolar disorder,” explains Dr Blair.
While other scientists have found genes associated with Bipolar, most of them haven’t stood up to scrutiny. The Sydney discovery has been verified in four independent study groups: two in the UK, one in Australia, and one in Bulgaria.
Bipolar disorder is a major psychiatric illness affecting around two people in every 100. Tragically, around one in six people suffering from the condition will commit suicide.
Mood-stabilising medications are typically prescribed to help control bipolar disorder. Lithium was the first mood-stabilising medication approved by the U.S. Food and Drug Administration (FDA) for treatment of mania. For decades it has been widely prescribed for the treatment bipolar disorder, yet no one knows for sure why it works.
“Lithium has a number of severe side effects that include tremor and weight gain. Kidney dysfunction may develop in a small proportion of patients when it is administered for long periods of time,” says Professor Mitchell.
This new research has raised the possibility that lithium exerts its therapeutic affect by altering FAT gene expression, as well as the expression of genes encoding FAT’s protein partners.
“Once we understand exactly what the FAT gene does, we will be able to develop better diagnostic tests for bipolar disorder. In the future, we hope our research will lead to new, targeted medicines specifically for bipolar disorder that don’t have the unpleasant side effects that lithium has,” says Dr Blair.
http://www.unsw.edu.au/
Feb 5, 2010
Paving the Way for Personalized Medicine
SACGHS has formed a task force to address the clinical utility of genetic testing—that is,.the usefulness of genetic tests for helping doctors choose more effective interventions for their patients. Assessing clinical utility is an important component of both personalized medicine and comparative effectiveness research, which analyzes interventions head-to-head to see which work better for different patients. The goal is to improve comparative effectiveness research by incorporating genetic tests, which would allow physicians to tailor treatments to individual patients based on their own DNA.
The Personalized Medicine Coalition held a conference last fall to promote the alignment of comparative effectiveness research with personalized medicine. This alignment is also a crucial aspect of the recommendations issued by the Institute of Medicine, which promoted research on both “diseases and conditions with the greatest aggregate effect on the health of the U.S. population, but also less common conditions that severely affect individuals invulnerable subgroups of the population.”
The Center for American Progress has also recognized the importance of ensuring that CER can “accelerate the discovery of approaches to individualized medicine and help providers cater to the specific needs of patients.” This will move medicine beyond the “one size fits all” therapies that result from the research provided by pharmaceutical companies to the FDA. SACGHS is taking an important step forward by identifying ways to assess the clinical utility of genetic tests. This was one of several recommendations CAP has made not just for advancing personalized medicine but also for improving the quality of genetic testing in the report, “Genetic Information Non-Discrimination.”
Genetics education and training will also be a major part of the SACGHS meeting agenda. The task force outlined its action plan in July of 2008 and has since set out to identify the needs of healthcare providers, the public health workforce, and the general public for genetic education. The task force also identified various types of case studies that it will use to analyze the current information gaps in genetic testing. This will require exploring the best way to gather and disseminate information about pharmacogenomic testing, newborn screening, diagnosis of single gene disorders, direct-to-consumer testing, and population genetics. The task force plans to release their report in the coming months. This is an important step, as the public must be “informed and educated about personalized medicine through outreach efforts, opportunities for public comment or input, and most importantly through transparency.”
Data sharing is also a major component of the agenda. Representatives from government, academia, health care systems, industry, and consumer groups will present different models for sharing genomic information. This will be followed by a discussion of health information technologies that aim to efficiently connect the data among these multiple sectors. In “Paving the Way for Personalized Medicine,” my co-author and I addressed both the positive developments as well as the missed opportunities on this front. In particular, we noted that HHS’s Health IT Standards Committee has not properly collaborated with outside networks that are working to devise consistent nomenclature so that genomic data can be utilized through health IT. We recommended this kind of collaboration so that HHS can leverage the expert resources available for combining cutting-edge genomic science with health IT.
The face of medicine is changing at a breakneck pace and a forum like the SACGHS meeting allows scientists, policymakers, innovators, service providers, and patients to work together to ensure that this new era of medical innovation serves the common good by being safe, effective, efficient, and equitable.
Feb 2, 2010
A gene test that predicts the risk of a stroke
Adults at risk of either prostate cancer or an erratic heart beat that can lead to strokes can now be identified early by genetic testing. About one in 20 elderly people suffer from atrial fibrillation, a condition in which turbulent blood flow raises the risk of blood clots, which can then lodge in the brain and cause a stroke.
Now an Icelandic company, deCODE, has announced in the journal Nature that it has found a variation in the human DNA sequence which raises the risk of atrial fibrillation, and used it as the basis of a test which will make it possible to identify those who will benefit the most from treatment. The firm's researchers found two "spelling mistakes" or single-letter variations in the human genetic code which increase the risk of atrial fibrillation by about 70 per cent and 40 per cent, doubling that risk if two copies of the variants are carried.
Because of the link with stroke, the company believes testing for these variants will provide doctors with a cost-effective means of identifying those who should be intensively monitored and reduce their risk by taking anticoagulant drugs. Passing abnormalities in heart rhythm are difficult to detect in many patients and it is impractical and too costly to conduct extended cardiac monitoring, even in patients who have had a stroke. The "spelling mistakes" in DNA linked with the risk were found through analysis of more than more than 300,000 common single-letter DNA changes in more than 5,000 Icelanders and were replicated in a further worldwide study of 18,000 subjects.
Dec 7, 2009
Overweight and Obesity
Nov 28, 2009
Genetica: test del Dna per scoprire l'infedeltà. Laboratorio invece del detective
Roma, 20 nov. (Adnkronos Salute) - Il tradimento coniugale si dimostra nel laboratorio d'analisi. Accade in Messico dove alcuni centri di diagnosi puntano alla conquista di un nuovo mercato, quello dell'infedeltà, proponendo test del Dna ad hoc per dimostrare scientificamente l'esistenza di un'amante. Il coniuge che ha un sospetto, infatti, si rivolge direttamente ai laboratori portando un indumento intimo, un lenzuolo, un bicchiere o persino un chewing-gum masticato per cercare tracce di saliva, sperma, peli o capelli dell'altro.
Con specifici test del Dna, consentiti nel Paese sudamericano anche senza l'autorizzazione dell'interessato, si può poi determinare se le tracce trovate appartengono al cliente o a qualcun altro. Queste analisi, pronte in circa una settimana, posso costare dai 200 ai 500 dollari (dai 135 euro ai 335 euro circa).
Questo nuovo business, appena avviato, in Messico ha avuto un successo immediato. "La richiesta di 'test d'infedeltà' - spiega Jorge Guillen, che dirige uno dei laboratori che propone queste analisi - è in continuo aumento. Mi è capitato di avere 50 richieste in una sola giornata. Ma è una cosa nuova per molti e ci sono molti fraintendimenti: molti clienti vengono da noi perché credono che l'infedeltà sia scritta nei geni".
Nov 20, 2009
Out of the hat of medical research
Of many interesting stories for us to blog about this week -- so many that they'll be spilling over into next week -- here's one that seems to represent a more sensible approach to disease than the relentless focus on genetics that we so commonly see. It's about a new effort by pharmaceutical companies to invest in vaccine development. The AP story says
Malaria. Tuberculosis. Alzheimer's disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler's diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it.
Another story of what seems to be money well-spent appears on the BBC website. Researchers have developed a new-fangled lab-on-a-chip that will allow easier, faster and cheaper diagnosis of dozens of diseases.
The device relies on an array of antibody molecules that are designed to latch on to the protein-based molecular markers of disease in blood.
The antibodies are chemically connected to molecules that emit light of a specific colour when illuminated - but only when they have bound to the disease markers.
Some of the vaccines in the pipeline won't pan out, but some surely will, and we can imagine the lab-on-a-chip device being useful in many settings, including medically underserved areas, so we find these stories rather heartening. The money being invested is private, not taxpayer money, but not long ago a lot of pharmaceutical money was being bet on personalized genomics, and so on, which our regular readers will recognize as efforts we wouldn't have put our money on. So, it's good to see that following the money takes us in a different direction these days -- industry sees a lot more promise in preventing and treating infectious disease than in fixing genes. Indeed, a lot more disease seems to be infectious than the age of genetics led us to believe.
The Fall of deCode Genetics
It's interesting to juxtapose these two stories with this story from the Wednesday New York Times that reports on the demise of a company established to "exploit the promise of the human genome", that is, to profit from what it could learn about genetic disease from the genealogies of Iceland. Predicated on the idea that common genetic variants would be found to explain most complex disease, deCode Genetics set out to find those variants in Iceland and then develop drugs to target them. But, it turns out that complex disease is too complex for that. Again, regular readers won't be surprised if we find it hard to suppress a little "told you so".
Now, here we want to be careful about the concepts -- and it's related to central issues in The Mermaid's Tale. Life is lived, day to day, on the molecular level. Infection is essentially attack from without, and the immune system tries to recognize molecular signatures of the invading soldiers, to latch onto them and destroy them. Vaccines traditionally help the immune system do that, by exposing it to harmless mimics of the real thing (dead viruses, so to speak).
There are countless infectious diseases, affecting of most body systems, and more and more complex 'chronic' diseases that were thought to be 'environmental' or 'genetic' in the traditional senses, seem to be turning out to have infectious or inflammatory components. Thus, enhanced abilities to make vaccines could have farther-reaching implications than has been thought.
The immune system is 'genetic' of course, and its functions are fairly close to genes in many ways. But there may be other and perhaps even surprising ways this subject can bring us back to genetics. We'll deal with them in a post in the near future....
Oct 30, 2009
Learning of Risk of Alzheimer’s Seems to Do No Harm
Oct 28, 2009
As genetic medicine races ahead, docs are left behind
Genetic tests that can help predict and refine a patient's response to drug therapy may be the first big thing in personalized medicine. But the vast majority of physicians don't know how to use them, a new survey finds.
Oct 25, 2009
Smart Genetics Shuts Its Doors
Oct 23, 2009
Jumping On Genetic Testing: The War of the SNPs
How many SNPs does it take to provide a definitive disease risk profile? Quite a few, apparently, as companies continue to pile them higher and deeper into genetic tests. Firms have bet that these tests will be widely adopted by physicians and the public to predict everything from risk of lung cancer among smokers, to prostate cancer, to Alzheimer’s disease, to baldness.
All told, about three dozen companies claim that they can provide genetic testing that predicts an individual’s risk of developing almost everything. “There is a bit of a wild wild west going on in terms of some of the DNA testing that’s out there,” said Francis S. Collins, M.D., Ph.D., the newly appointed NIH head, in an interview with CBS News in September 2008 with regard to a new offering from Smart Genetics purporting to predict susceptibility to Alzheimer’s disease (AD).
“Some of it is done by reputable companies, but there are some that are even unscrupulous who will offer you tests or DNA variations that, frankly, you’re not sure what they mean at all.” Smart Genetics stopped offering its controversial Alzheimer’s Mirror genetic test just eight months after introducing it, and the company subsequently shut its doors.
Oct 13, 2009
CyGene Launches New Website for Direct-to-Consumer Genetic Test Marketing
CORAL SPRINGS, Fla., Aug. 26, 2009 (GLOBE NEWSWIRE) -- CyGene Laboratories Inc. (Pink Sheets:CYGE) today announced that it has launched a new website, www.cygenedirect.com, where consumers can get information and order predictive genetic tests geared to inform consumers about specific options to help improve health, while maintaining anonymity. The consumer-friendly website features easy online ordering of the company's products. The site also includes comprehensive personal assessment information and details about potential benefits of the products, as well as detailed consumer information about genetics and genetic testing. The site also features links to the company's blog and its social media sites. "People have a unique opportunity with CyGene to start learning about their personal genetics and how their genes may impact their lives. Generally, this will be their first brush with this exciting new field of science and our new website can help them find out how genetic testing works, which kits are best for them, and how they can be used to improve overall quality of life and athletic performance," said Martin Munzer, president and CEO of CyGene. "And our new site makes it easier than ever for people to get the information and products they're looking for with guaranteed anonymity." The new creative direction of CyGeneDirect.com comes by way of Infinity Arts. "Our objective for CyGeneDirect.com was to re-invigorate the consumer website to be more compelling; easy to understand, navigate and relate to, while strategically improving visibility on the internet via search engines and online social mediums," said Michael Leahy, CEO for Infinity Arts. About CyGene Laboratories Inc. CyGene Laboratories Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method also allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available. For more information about CyGene Laboratories and its products, visit the Company's website at www.CyGeneDirect.com.
Oct 10, 2009
Genetic Testing in France
By Tamar G. McLachlan
Well we visited The Geneticist Today; a Professor Labrune, at the Hospital Beclere (somewhere on the outskirts of Paris). Actually, it is in the direction of Versailles and my husband commented on how exciting it is to be in a place where we could hop over to Versailles after a doctor's visit. The fact that I was a.) freezing b.) nauseous c.) trying not to pass out from the bus ride kept me from agreeing enthusiastically.
We secured this appointment in the complex yet sincere way that the French do everything. After many emails and several intense consults with friends and family, I was convinced (not to mention a bit panicked) that it was essential that I be tested for a variety of genetic diseases (including the Jewish ones). Apparently, even though neither my husband nor I have any history of genetic diseases of any sort in our families, this testing is common in the USA and so we were advised to pursue it.
In my normal pre-pregnancy state I tend a TAD towards the anxious side. In my pregnant state with hormones running rampant I am pretty close to hysteria much of the time. I searched the internet, examined pregnancy books and grilled friends and family doctors at home about the dangers of genetic illnesses. Visions of deformed babies and childhood deaths haunted me. Meanwhile, my Parisian GYN looked at me blankly when I mentioned that I must be tested for a variety of diseases, a.s.a.p. She had no idea what I was asking.
True to French form, after my doc greeted my anxieties with a look of curiosity and confusion, she set off on a search through the hospital to find the answers to my questions. After a forty-five minute tour of the hospital, consulting with a variety of physicians, she returned to her office (where I was not-so-patiently waiting) to tell me that this hospital does not in fact perform such screening (what?! This is common practice in the USA!)
In fact, since it is a specialized concern, she would refer me to a genetics specialist who would give me an individual consult.
Frustrated that I couldn't just have the blood test done and over with then and there (I abhor blood tests), I grudgingly took the information and waited for my appointment. This was one of my many lessons in the French health system, which is related to the French culture in general. The French, as a whole, feel entitled to good care. They feel it is their right and their privilege to seek professional advice and help when and where they want it. Because of socialized medicine, there is no hesitancy to refer to specialists. Likewise, there is no hurry to pack many patients into a short time frame, scheduling appointments 15 minutes apart as in the USA.
In two months, I have visited my GYN four times and only once has it been for an actual exam. The others were all consults or opportunities for me to address concerns and get information. Two of these consults included my husband. When I call my doctor, I actually reach her directly on the phone. If I have anything other than a brief question, she schedules an appointment to talk in person. Sometimes these appointments last up to an hour. My private insurance (since I don't qualify for social security) covers 90% of all my care.
Therefore the entire mentality is different. French people often seek several consultations from several doctors to get different opinions. They are not restricted by primary care referrals and 15 minute sessions. Patients hold onto their own medical records, lab reports and x-rays.
So my husband and I were sent to see Professor Labrune, the Genetics specialist. We had an appointment schedule for 9:30 am and I was so anxious about finding the office and arriving on time that I couldn't sleep the night before. Clay calmly planned out our subway route. The next morning we left before dawn (the sun doesn't rise until 8:30 a.m. --a real downer in the early morning) and shivered our way to the metro. One metro and one extremely nauseating bus ride later, we found ourselves in front of what looked like a warehouse. Armed with only the Professor's name (and no other information), we wandered around the chain link fence, looking for the appropriate entrance. We finally found a sign directing us to Prof Labrune Porte 33. Hesitantly, we entered the "porte', which was actually a delivery entrance. Following a bakery delivery truck in through the door, we found ourselves in a garage, wondering where the heck the doctor's office was. We wandered our way through a door (having asked a confused delivery man where to go), which led to a maze of white hallways. By this time, I was anxious, nauseous and desperately had to use the bathroom, which luckily I found easily. No matter that it was an employee only entrance; this was a desperate situation (besides, I figured "hey I'm a pregnant lady! Back off!"), I could hear my husband asking for directions in the hallway. It turns out that we had come in through the kitchen entrance and were now in the back of the hospital cafeteria. Clearly not where Prof Labrune must be waiting.
We stumbled our way through an ER section, past a row of empty gurneys and up a flight of stairs leading to the information desk. The very friendly woman behind the desk directed us around the corner to pediatrics, where we sat, among an assortment of toddlers and parents, waiting to be seen. My husband beamed at the darling children; I tried to keep from throwing up or passing out.
"Look" I turned to him, "I'm not big on blood tests or hospitals and my French is headed out the window so if you could be the proactive team member here, that would be great. I mean, how the hell do I ask about being a carrier for Taysachs disease in French?"
I couldn't have been more off base. The Professor was a charming, gentle, quiet and patient man who first took our family history. Then he patiently explained the various diseases we were concerned about (in too much detail), their origins (not really necessary) and the percentage of risk. I couldn't believe that we were having this conversation in French! And I actually understood it! Not that I "understood" it. I understood the words. And the context. I was just reveling in my linguistic breakthrough when he pulled out a piece of paper and started to diagram the cell mutation related to one of the diseases. (At this point I had to admit defeat. Not due to language barriers but due to my own science learning disability. Once someone starts talking cells and DNA, I start to lose it). Not wanting to be rude (he was enamored with his description of some particular cell growth), I steered the conversation back to our family trees and what tests would be appropriate for us.
This led to the obligatory piece of any professional consult in France: the paperwork. In order to be tested we must solemnly sign the agreement to show that we fully understood the solemn oath of his professional boundaries (confidentiality, professional courtesy, professional boundaries and a myriad of other issues which seemed to pertain mainly to his limitations as a mortal and not as an agent of God). Then there would be the second set of papers authorizing release of this information to my doctor, which could only be sanctioned with my personal authority. Otherwise, our test results would remain in the secrecy of Professor Labrune. He took this very seriously. An oath of privacy.
After we satisfactorily signed and sanctioned the paperwork, we were led next door to the lab technician to have our blood drawn. Just the thought of this process made me queasy, but my husband, who is quite an experienced blood donor, asserted that this was one of the most professional outfits he had ever seen. Not only were the technician (and her assistant) extremely friendly and caring, they treated us like dear friends, expressing extreme concern over my obvious distaste for the process. Offers of juice, attempts to make jokes, were all lost on me as I did my best to disassociate from the process. They even recommended an anesthetic patch that can be purchased in the pharmacy, to numb the area to be pricked.
I stumbled out of the technician's office (desperate to get away from any sign of B-L-O-O-D) and we returned to the information desk to settle our bill. Having been quoted a fee of $1000 to have this exact procedure (consult and tests) done in Boston, we were shocked to be asked to pay a total of 32.10 euros. I must have heard wrong. She must have meant 300 euros and in my light -headed state I was getting the numbers wrong. Nope. 23 euros for the consult with the Professor and 4 euros for our tests, plus a couple of euros miscellaneous. "You do have insurance that will reimburse you?" she asked me with a concerned look.
I am overwhelmed by the quality of service, professionalism and State of the Art care we have experienced here. I'm sure some of it is luck. But boy have we been lucky.
Aug 1, 2009
Will your genetic source code be open or closed?
The use of genetics in finding cures to diseases, now calledgenomics, may be the key to both your future health and economic growth.
Starting with the sequencing of a virus DNA by Fred Sanger in the 1970s, and extending to the sequencing of the entire human genome in 2001, scientists have been consumed with the task of decoding your genes, the genomes of disease, and manipulating genes to make new medicine.
Most of the work has been done in what computer scientists would call “closed source,” in that genomes are subject to patent rights.
But there have long been efforts to carve out a place for open source in the effort, starting with the donation of the Human Genome Project’s work in the government’s GenBank system. Versions of the H1N1 flu virus are alsobeing submitted to GenBank.
The open source advocates at O’Reilly point out that open source software has also been part of that mix, personifying that effort in David Dooling(above), assistant director for infomatics at the Genome Center in St. Louis. His work uses a lot of open source software.
But there is a larger question, one I want readers to weigh in on.
Where will the most progress come from? Does the path to cure lead through the private ownership of genetic codes, or will we make more progress is genes are part of the open source world?
Jul 29, 2009
Our genetic code should be no big secret
We should be less frightened of wider access to our DNA profile — those in the know are offering theirs up for public view
The 1997 movie Gattaca sets out one of the great dystopias of science fiction. Genetic technology has divided humanity. Social class is determined by DNA. The “valids”, with sound genetic profiles, dominate the top jobs and political power. The “in-valids”, with flawed genomes, form a genetic underclass.
The film’s vision highlights a deep concern about the coming genomic age: that as science reveals more about the human genetic code it will not only herald new approaches to medicine but also create new ways to discriminate and invade privacy. Employers might select candidates according to genetic aptitude. Health insurers could refuse cover to people with high-risk genomes. And personal information about our health and personalities might be revealed for all to see.
Such fears have built a consensus that ethical use of genetic information must be founded on strict privacy. If DNA profiles are to improve treatment and prevention of disease without compromising liberty, access must be controlled. They belong to individuals and should not be disclosed without their consent. The prevailing assumption is that we should guard such data closely.
It is far from clear, however, that this assumption is correct. True genetic privacy may be impossible to achieve — and many of the scientists whose work is driving the DNA revolution believe that the costs of trying will outweigh the benefits. Some are even backing their words with action, by publishing their own genetic data on the internet.
The fantasy that it is possible to prevent unauthorised access to a person’s DNA was exposed in March by Peter Aldhous and Michael Reilly, of New Scientist. Aldhous drank from a glass and gave it to Reilly, who used commercial services to extract his colleague’s genetic profile. It is illegal in Britain to test DNA like this without consent. But the process is so cheap and simple, and the chance of detection so slim, that this offers little practical protection. We leave so much DNA wherever we go that we cannot expect to keep it to ourselves. Legislation might be a deterrent, but it will not prevent unauthorised use.
Even if genetic data could be comprehensively protected, it doesn’t automatically follow that it should be. In making a fetish of DNA, we may be limiting its usefulness. If science is to unravel the medical implications of genetic variations between individuals, to personalise and improve healthcare, it will be necessary to compare the DNA sequences of hundreds of thousands of people. A culture of privacy will hold this back while secreting information that may be less sensitive than it seems.
Certainly, the great and the good of human genetics do not feel that they have much to lose by sharing this data. Some are challenging the privacy assumption by example. When the genetics pioneer Craig Venter became the first person to have all six billion DNA letters of his genome sequenced he published the lot. James Watson, the co-discoverer of the double helix, has done likewise, redacting only the status of a gene linked to Alzheimer’s because he did not want to know the information himself. Kari Stefánsson, of deCODE Genetics, which sells personal DNA tests, allows his customers to compare their data with his.
George Church, of Harvard University, has gone a stage further. The founder of the Personal Genome Project (PGP), and its first participant, has published not only his complete genome sequence but also his medical records and other physical details. He aims to recruit 100,000 volunteers to do the same.
The nine other recruits to the PGP’s pilot phase are all people who know their stuff: they include the psychologist Steven Pinker, John Halamka, Dean of Technology at Harvard Medical School, and Misha Angrist, a geneticist at Duke University in North Carolina. Another 13,000 have joined a waiting list to take part. By putting their information in the public domain, participants hope to exploit “crowd-sourcing”, the notion that allowing anyone to work on a problem will lead to it being solved more swiftly. The phenomenon underlies the success of Linux open-source software and Wikipedia. It could soon be driving genetic discoveries as well.
This will have individual benefits as well as social ones. When Church placed his medical records on the internet he was contacted by a doctor who suggested a useful change to his cholesterol medication. Interpretations of open data are more likely to help than harm.
The prophets of open-source genomics are unruffled because the perceived need for absolute secrecy is also based on a misunderstanding of heritability. While most people think of genetics as a deterministic science, this is rarely so. Most genes that influence health have a probabilistic effect, raising or lowering risk by small margins. Most people with the Alzheimer’s risk gene , for example, will not get Alzheimer’s. It would not only be wrong to judge somebody’s intellect, skills or good health by their ownership of particular genetic variations — it would be profoundly misleading.
All of us carry risky variants: there is no such thing as a perfect genome. That should help to prevent discrimination: if insurers were to exclude everyone with a raised genetic risk of this or that they would rapidly go bankrupt. If the market fails, companies can be banned by law from demanding genetic test results; the US has already done this, and the UK has a voluntary moratorium.
Nobody should be forced to reveal genetic data, which should be published only with the informed consent of the owner; the PGP takes the “informed” part so seriously that it requires participants to pass a genetic literacy test. But it is instructive that so many of those who best understand the mechanics of the genome see so little to fear. Given wider understanding of the probabilistic nature of genetics, their choice to go public is one that many more of us could emulate.